CNS Pharmaceuticals CNSP

$ 0.11 -1.73%

Quarterly report 2024-Q3
added 11-14-2024

CNS Pharmaceuticals Balance Sheet 2011-2024 | CNSP

Annual Balance Sheet CNS Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-13.6 M	-7.24 M	34.2 K	11.3 K	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	6.13 M	4.92 M	2.59 M	1.91 M	311 K	-	-	-	-	-	-	-	-
Total Liabilities	6.13 M	4.92 M	2.59 M	1.91 M	311 K	1.23 M	221 K	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-69.6 M	-50.7 M	-35.4 M	-20.9 M	-11.5 M	-7.61 M	-219 K	-	-	-	-	-	-
Total Assets	1.7 M	13.1 M	8.76 M	15.9 M	7.91 M	683 K	162 K	-	-	-	-	-	-
Cash and Cash Equivalents	549 K	10.1 M	5 M	14 M	7.24 M	555 K	-	-	-	-	-	-	-
Book Value	-4.43 M	8.13 M	6.16 M	13.9 M	7.6 M	-549 K	-58.5 K	-	-	-	-	-	-
Total Shareholders Equity	-4.43 M	8.13 M	6.16 M	13.9 M	7.6 M	-549 K	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet CNS Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	4.06 M	6.76 M	6.09 M	6.13 M	4.07 M	4 M	3.92 M	4.92 M	1.24 M	924 K	1.07 M	2.14 M	2.41 M	1.83 M	1.9 M	1.91 M	1.91 M	1.91 M	1.91 M	311 K	311 K	311 K	311 K	1.23 M	1.23 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-81.2 M	-75.6 M	-73.1 M	-69.6 M	-64.2 M	-59.7 M	-55.6 M	-50.7 M	-44.8 M	-41.3 M	-37.8 M	-35 M	-32.2 M	-28.4 M	-24.6 M	-20.9 M	-20.9 M	-20.9 M	-20.9 M	-11.5 M	-11.5 M	-11.5 M	-11.5 M	-7.61 M	-7.61 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	7.41 M	2.47 M	1.66 M	1.7 M	2.33 M	6.45 M	7.41 M	13.1 M	9.64 M	12.4 M	15.9 M	8.76 M	11.5 M	14.2 M	13.1 M	15.9 M	15.9 M	15.9 M	15.9 M	7.91 M	7.91 M	7.91 M	7.91 M	683 K	683 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	6.97 M	1.49 M	815 K	549 K	910 K	4.28 M	5.11 M	10.1 M	7.03 M	8.96 M	12.4 M	5 M	8.33 M	6.89 M	11.1 M	14 M	14 M	14 M	14 M	7.24 M	7.24 M	7.24 M	7.24 M	283 K	283 K	-	-	111 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	3.35 M	-4.29 M	-4.43 M	-4.43 M	-1.74 M	2.45 M	3.49 M	8.13 M	8.39 M	11.5 M	14.8 M	6.62 M	9.1 M	12.4 M	11.2 M	13.9 M	13.9 M	13.9 M	13.9 M	7.6 M	7.6 M	7.6 M	7.6 M	-549 K	-549 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	3.35 M	-4.29 M	-4.43 M	-4.43 M	-1.74 M	2.45 M	3.49 M	8.13 M	7.57 M	10.7 M	14 M	6.62 M	9.1 M	12.4 M	11.2 M	13.9 M	13.9 M	13.9 M	13.9 M	7.6 M	7.6 M	7.6 M	7.6 M	-549 K	-549 K	-198 K	35 K	-58.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency